FDA
-
-
-
-
-
-
-
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
-
-
-
-
-
-
-
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Enveric Biosciences Announces Registration of Five Trademarks
-
-
-
-
-
-
-
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
-
-
-
-
-
-
-
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
-
-
-
-
-
-
-
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

